论文部分内容阅读
全球约2亿人(3%)感染丙型肝炎病毒(HCV),并且每年约有300万新增病例。HCV感染者中约70%将发展成慢性丙型肝炎(CHC)。若无有效治疗,其中约25%将在25年内发展成肝硬化,每年仅因肝硬化导致的病死率可达3%。由于标准治疗方案的疗效、不良反应等方面存在诸多问题,因此,新型抗HCV药物,尤其是直接抗病毒药物的研发成为研究的热点。目前,直接抗丙型肝炎药物主要分3类:NS3/4A蛋白酶抑制剂、NS5B聚合酶抑制剂和NS5A蛋白抑制剂。其中/蛋白酶抑制剂特拉泼维
About 200 million people (3%) worldwide are infected with the hepatitis C virus (HCV) and have an estimated 3 million new cases each year. About 70% of HCV-infected individuals will develop chronic hepatitis C (CHC). In the absence of effective treatment, about 25% of them will develop cirrhosis within 25 years, with an annual mortality rate of up to 3% due to cirrhosis alone. Because of the curative effect of standard treatment regimens and adverse reactions, there are many problems. Therefore, the research and development of novel anti-HCV drugs, especially direct antiviral drugs, has become a hot research topic. Currently, direct anti-hepatitis C drugs are divided into three categories: NS3 / 4A protease inhibitors, NS5B polymerase inhibitors and NS5A protein inhibitors. Among them / protease inhibitor Travolta